Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118370 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30977677 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29613402 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12537019 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1486216 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29907974 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29352409 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29519824 | 0.95 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL6742006 | 0.92 | MDM4 (0.55) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29451083 | 0.91 | CASP3 (0.59) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583889-B2 | Cell penetrating peptides | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-03-24 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-119954892-A | Whole-process targeting polypeptide, drug complex, drug delivery system and application thereof | 复旦大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-3647319-B1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER SHANGHAI CO LTD (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119638792-A | Polypeptide PT-09014 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119504947-A | Polypeptide PT-1323 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119320430-A | Polypeptide PT-1509 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024250929-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国医学科学院医药生物技术研究所 | 2024-12-12 | — | — | WO | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-119019491-A | General serine short peptide synthesis method | 华东理工大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2022162332-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-08-04 | — | — | WO | disclosed |
| US-20220226479-A1 | CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION | UNIVERSITY OF TSUKUBA (JP) | 2022-07-21 | — | — | US | disclosed |
| CN-109134610-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | disclosed |
| CN-111978371-B | Polypeptide derivative and application thereof in field of medicine | 成都诺和晟泰生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022082006-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3973990-A1 | PROMOTOR FOR PERMEATION INTO CELL LAYER, COMPOSITION FOR FACILITATING DRUG AGENT ABSORPTION, AND PHARMACEUTICAL COMPOSITION | University of Tsukuba (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022054062-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | BAR ILAN UNIVERSITY (IL) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-109311910-B | Tacrolimus conjugates, compositions thereof, and uses thereof | 杜兰教育基金委员会 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-12583889-B2 | Cell penetrating peptides | SLC2A3, SLC1A5, SLC2A1 | MDM4 4625/4885TP53 1977/4885CASP3 854/4885 |
| US-20220226479-A1 | CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCB1, SLC10A1 | MDM4 4535/4885TP53 4108/4885CASP3 2986/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, MYD88, CD47 | MDM4 3186/4885TP53 788/4885CASP3 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.